RFG Advisory’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $10.2M | Buy |
40,584
+143
| +0.4% | +$30.8K | 0.16% | 94 |
|
|
2026
Q1 | $8.8M | Buy |
40,441
+500
| +1% | +$111K | 0.16% | 95 |
|
|
2025
Q4 | $9.13M | Buy |
39,941
+831
| +2% | +$189K | 0.17% | 94 |
|
|
2025
Q3 | $9.06M | Sell |
39,110
-1,714
| -4% | -$349K | 0.19% | 94 |
|
|
2025
Q2 | $7.58M | Buy |
40,824
+2,380
| +6% | +$442K | 0.18% | 91 |
|
|
2025
Q1 | $8.05M | Buy |
38,444
+11,628
| +43% | +$2.26M | 0.22% | 73 |
|
|
2024
Q4 | $4.77M | Sell |
26,816
-4,650
| -15% | -$855K | 0.13% | 121 |
|
|
2024
Q3 | $6.21M | Sell |
31,466
-1,434
| -4% | -$268K | 0.19% | 89 |
|
|
2024
Q2 | $5.64M | Buy |
32,900
+1,821
| +6% | +$302K | 0.18% | 95 |
|
|
2024
Q1 | $5.66M | Sell |
31,079
-2,407
| -7% | -$415K | 0.19% | 87 |
|
|
2023
Q4 | $5.19M | Sell |
33,486
-324
| -1% | -$47.2K | 0.2% | 84 |
|
|
2023
Q3 | $5.04M | Buy |
33,810
+2,191
| +7% | +$322K | 0.23% | 72 |
|
|
2023
Q2 | $4.26M | Buy |
31,619
+1,471
| +5% | +$216K | 0.19% | 89 |
|
|
2023
Q1 | $4.8M | Buy |
30,148
+360
| +1% | +$55K | 0.24% | 83 |
|
|
2022
Q4 | $4.33M | Buy |
29,788
+1,297
| +5% | +$199K | 0.22% | 86 |
|
|
2022
Q3 | $4.23M | Buy |
28,491
+775
| +3% | +$111K | 0.24% | 82 |
|
|
2022
Q2 | $3.83M | Sell |
27,716
-1,197
| -4% | -$183K | 0.22% | 79 |
|
|
2022
Q1 | $4.69M | Sell |
28,913
-3,490
| -11% | -$507K | 0.3% | 51 |
|
|
2021
Q4 | $4.39M | Buy |
32,403
+105
| +0.3% | +$12.4K | 0.3% | 51 |
|
|
2021
Q3 | $3.48M | Buy |
32,298
+2,989
| +10% | +$342K | 0.29% | 54 |
|
|
2021
Q2 | $3.3M | Buy |
29,309
+1,600
| +6% | +$180K | 0.29% | 54 |
|
|
2021
Q1 | $3M | Buy |
27,709
+1,236
| +5% | +$132K | 0.33% | 53 |
|
|
2020
Q4 | $2.84M | Buy |
26,473
+608
| +2% | +$58.4K | 0.37% | 56 |
|
|
2020
Q3 | $2.27M | Buy |
25,865
+1,501
| +6% | +$141K | 0.32% | 65 |
|
|
2020
Q2 | $2.39M | Buy |
24,364
+2,165
| +10% | +$191K | 0.37% | 55 |
|
|
2020
Q1 | $1.69M | Buy |
22,199
+3,068
| +16% | +$261K | 0.32% | 63 |
|
|
2019
Q4 | $1.69M | Buy |
19,131
+1,365
| +8% | +$113K | 0.29% | 71 |
|
|
2019
Q3 | $1.34M | Buy |
17,766
+1,557
| +10% | +$107K | 0.27% | 74 |
|
|
2019
Q2 | $1.18M | Buy |
16,209
+2,451
| +18% | +$193K | 0.27% | 77 |
|
|
2019
Q1 | $1.11M | Sell |
13,758
-1,694
| -11% | -$139K | 0.28% | 75 |
|
|
2018
Q4 | $1.43M | Sell |
15,452
-7,285
| -32% | -$641K | 0.35% | 52 |
|
|
2018
Q3 | $2.15M | Buy |
+22,737
| New | +$2.16M | 0.56% | 39 |
|
|
2018
Q2 | – | Sell |
-14,190
| Closed | -$1.34M | – | 211 |
|
|
2018
Q1 | $1.34M | Sell |
14,190
-29
| -0.2% | -$3.19K | 0.5% | 36 |
|
|
2017
Q4 | $1.41M | Buy |
14,219
+283
| +2% | +$26.7K | 0.66% | 34 |
|
|
2017
Q3 | $1.26M | Sell |
13,936
-1,444
| -9% | -$110K | 0.78% | 23 |
|
|
2017
Q2 | $1.1M | Sell |
15,380
-670
| -4% | -$45K | 0.76% | 20 |
|
|
2017
Q1 | $1.04M | Buy |
16,050
+7,698
| +92% | +$484K | 0.79% | 25 |
|
|
2016
Q4 | $526K | Hold |
8,352
| – | – | 0.5% | 35 |
|
|
2016
Q3 | $526K | Sell |
8,352
-9,927
| -54% | -$643K | 0.48% | 36 |
|
|
2016
Q2 | $1.13M | Hold |
18,279
| – | – | 0.98% | 15 |
|
|
2016
Q1 | $1.04M | Buy |
18,279
+12,328
| +207% | +$687K | 0.82% | 18 |
|
|
2015
Q4 | $353K | Sell |
5,951
-1,640
| -22% | -$94.5K | 0.26% | 31 |
|
|
2015
Q3 | $413K | Sell |
7,591
-1,889
| -20% | -$123K | 1.33% | 15 |
|
|
2015
Q2 | $637K | Buy |
+9,480
| New | +$619K | 0.29% | 59 |
|
Other funds holding ABBV
RFG Advisory's ABBV Position: Q2 2026 in Review
RFG Advisory increased its AbbVie (ABBV) stake by 0.35% in Q2 2026, buying an estimated $30.8K and bringing the position to 40,584 shares worth $10.2M. The position accounts for 0.16% of the portfolio, ranked #94.
RFG Advisory first reported a position in ABBV in Q2 2015 and has held it in 44 quarters since. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- RFG Advisory held 40,584 shares of AbbVie worth $10.2M as of Q2 2026.
- RFG Advisory bought 143 AbbVie shares in Q2 2026, an estimated $30.8K.
- AbbVie made up 0.16% of RFG Advisory's portfolio in Q2 2026, its #94 holding.
- RFG Advisory first reported a position in AbbVie in Q2 2015 and has held it in 44 quarters since.
- 4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on RFG Advisory's 13F filing for Q2 2026, filed 15 Jul 2026.